In reply: Aspirin desensitization for aspirin‐exacerbated respiratory disease in the era of biologics: Clinical perspective.

In addition, the reported efficacy of type 2 biologic therapy varies significantly by molecular target and is not universal to all patients with uncontrolled nasal polyps. It is only through a multidisciplinary approach with close collaboration between allergy and otolaryngology disciplines that we will be able to maximize the effect of these treatments and advance patient care. We read with great interest Dr Bosso's recent correspondence.1 In that communication he nicely describes the emergence of aspirin therapy after desensitization (ATAD), as type 2 biologics represent highly promising therapies in the treatment of our most recalcitrant patients. [Extracted from the article]